Common junctional plaque protein. The membrane- associated plaques are architectural elements in an important strategic position to influence the arrangement and function of both the cytoskeleton and the cells within the tissue. The presence of plakoglobin in both the desmosomes and in the intermediate junctions suggests that it plays a central role in the structure and function of submembranous plaques. Acts as a substrate for VE-PTP and is required by it to stimulate VE- cadherin function in endothelial cells. Can replace beta-catenin in E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton. Homodimer. Component of an E-cadherin/ catenin adhesion complex composed of at least E-cadherin/CDH1 and gamma- catenin/JUP, and possibly alpha-catenin/CTNNA1; the complex is located to adherens junctions. The stable association of CTNNA1 is controversial as CTNNA1 was shown not to bind to F-actin when assembled in the complex. Interacts with MUC1. Interacts with CAV1. Interacts with PTPRJ. Interacts with DSC2. Belongs to the beta-catenin family. Note: This description may include information from UniProtKB.
Protein type: Cytoskeletal; Motility/polarity/chemotaxis
Cellular Component: actin cytoskeleton; apicolateral plasma membrane; catenin complex; cell-cell adherens junction; cytoplasm; cytosol; desmosome; fascia adherens; focal adhesion; intercellular junction; intermediate filament; internal side of plasma membrane; lateral plasma membrane; membrane; nucleus; plasma membrane; Z disc
Molecular Function: alpha-catenin binding; cadherin binding; cell adhesion molecule binding; protein binding; protein kinase binding; protein phosphatase binding; structural molecule activity; transcription coactivator activity
Biological Process: cell adhesion; cell migration; cell-cell adhesion; detection of mechanical stimulus; positive regulation of protein import into nucleus; positive regulation of transcription factor activity; protein heterooligomerization; regulation of cell proliferation; skin development
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.